Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2007-11-13
2007-11-13
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
Reexamination Certificate
active
11588308
ABSTRACT:
The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection.
REFERENCES:
patent: 2086585 (1937-07-01), Taub et al.
patent: 2087132 (1937-07-01), Taub et al.
patent: 2108765 (1938-02-01), Domagk
patent: 2209383 (1940-07-01), Bock
patent: 2439969 (1948-04-01), Fourneau
patent: 2445393 (1948-07-01), Fourneau
patent: 2513747 (1950-07-01), Sallman et al.
patent: 2606909 (1952-08-01), Blicke
patent: 2689790 (1954-09-01), Mowry et al.
patent: 2950253 (1960-08-01), Kling et al.
patent: 3054678 (1962-09-01), Michener et al.
patent: 3694473 (1972-09-01), Eibl et al.
patent: 4093714 (1978-06-01), Tolman et al.
patent: 4096278 (1978-06-01), Queuille
patent: 4119714 (1978-10-01), Kny et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4221732 (1980-09-01), Oette et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4291024 (1981-09-01), Turcotte
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4426525 (1984-01-01), Hozumi et al.
patent: 4444766 (1984-04-01), Bosies et al.
patent: 4471113 (1984-09-01), MacCoss
patent: 4540521 (1985-09-01), Garst et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4619917 (1986-10-01), Lee et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4661509 (1987-04-01), Gordon et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4797479 (1989-01-01), Shuto et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4826823 (1989-05-01), Cook et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837023 (1989-06-01), Eibl
patent: 4841039 (1989-06-01), Chu et al.
patent: 4880782 (1989-11-01), Eckstein et al.
patent: 4921951 (1990-05-01), Shuto et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 4997761 (1991-03-01), Jett-Tilton
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5116992 (1992-05-01), Braquet et al.
patent: 5138045 (1992-08-01), Cook et al.
patent: 5221696 (1993-06-01), Ke et al.
patent: 5496546 (1996-03-01), Wang et al.
patent: 5512671 (1996-04-01), Piantadosi et al.
patent: 5614548 (1997-03-01), Piantadosi et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5770584 (1998-06-01), Kucera et al.
patent: 5830905 (1998-11-01), Diana et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5891874 (1999-04-01), Colacino et al.
patent: 5922757 (1999-07-01), Chojkier
patent: 5962437 (1999-10-01), Kucera et al.
patent: 5985854 (1999-11-01), Kozak
patent: 6030960 (2000-02-01), Morris-Natschke et al.
patent: 6034134 (2000-03-01), Gold et al.
patent: 6077837 (2000-06-01), Kozak
patent: 6136796 (2000-10-01), Kozak
patent: 6166089 (2000-12-01), Kozak
patent: 6670341 (2003-12-01), Kucera et al.
patent: 7141557 (2006-11-01), Kucera et al.
patent: 2004/0082242 (2004-04-01), Bottger et al.
patent: 3726945 (1989-02-01), None
patent: 3934 820 (1991-04-01), None
patent: 4010228 (1991-10-01), None
patent: 19914474 (1999-10-01), None
patent: 0094586 (1983-11-01), None
patent: 0109255 (1984-05-01), None
patent: 0142333 (1985-05-01), None
patent: 0145303 (1985-06-01), None
patent: 0146258 (1985-06-01), None
patent: 0252310 (1988-01-01), None
patent: 0310109 (1989-04-01), None
patent: 0335396 (1989-04-01), None
patent: 0348859 (1990-01-01), None
patent: 0350287 (1990-01-01), None
patent: 0416401 (1991-03-01), None
patent: 0434450 (1991-06-01), None
patent: 0506704 (1991-07-01), None
patent: 0632048 (1995-01-01), None
patent: 1561630 (1969-03-01), None
patent: 2239243 (1991-06-01), None
patent: 42-13841 (1967-08-01), None
patent: 49-100224 (1974-09-01), None
patent: 61-238793 (1986-10-01), None
patent: 10-293129 (1989-01-01), None
patent: 08-268890 (1996-10-01), None
patent: 10-101591 (1998-04-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 90/05736 (1990-05-01), None
patent: WO 90/15601 (1990-12-01), None
patent: WO 91/05558 (1991-05-01), None
patent: WO 91/09602 (1991-07-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19726 (1991-12-01), None
patent: WO 92/03462 (1992-03-01), None
patent: WO 92/04887 (1992-04-01), None
patent: WO 92/06192 (1992-04-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 93/08807 (1993-05-01), None
patent: WO 93/16091 (1993-08-01), None
patent: WO 93/16092 (1993-08-01), None
patent: WO 93/17020 (1993-09-01), None
patent: WO 93/21191 (1993-10-01), None
patent: WO 94/28908 (1994-12-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 01/19320 (2001-03-01), None
Aggarwal, S. K. et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine”,J. Med. Chem., 33, 1505-10 (1990).
Alt M. et al., “Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation”,Archives of Virology142:589-599, 1997.
Alt M. et al., “Specific Inhibition of Hepatitis C Viral GeneExpression by Antisense Phosphorothioate Oligodeoxynucleotides”,Hepatoloy22:707-717, Sep. 1995.
Amari et al., “Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phase High-Performance Liquid Chromatography,”Journal of Chromatography, 590 (1992), 153-161.
Anderson, L. J. et al., “Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies”,Journal of Infectious Diseases, 151:626-633 (Apr. 1985).
Attwood, M. R. et al., “The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase”,Antiviral Chemistry and Chemotherapy, 10:259-273, Sep. 1999.
Bartlett, “Antiretroviral Therapy in Patients with HIV Infection”, 1996,Infectious Diseases in Clinical Practice5:172-179.
Battaglia, A.M. et al., “Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection”,The Annals of Pharmacotherapy34:487-494, Apr. 2000.
Berdel et al., “Cytotoxicity of Thioether Lysophospholipids in Leukemias and tumors of Human Origin,”Cancer Research, vol. 43 (1983), 5538-5543.
Berenguer, M. et al., “Hepatitis C Virus in the Transplant Setting”,Antiviral Therapy3(Suppl. 3):125-136, 1998.
Boldanova, N. B. et al., “Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis”,Vopr. Med. Khim, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986).
Bosies, E. et al., “Preparation of Lecithin Analogs as Retrovirucides and Virucides”, Chemical Abstracts, 115CA; 72142p 1991.
Braekman et al., “Pharmacokinetics (PK) of Depocyt™ after Intrathecal Administration for the Treatment of Leptomeningeal Metastases (LM)”, 1997,Proc. Amer. Soc. for Clinical Oncology, Abstract #810.
Caliendo, A. M. et al., “Combination Therapy for Infection Due to Human Immunodeficiency Virus Type 1”,Clinical Infectious Diseases, vol. 18, pp. 516-524, 1994.
Capizzi, “Curative Chemotherapy for Acute Myeloid Leukemia: the Development of High-Dose Ara-C from the Laboratory to Bedside”, 1996,Investigational New Drugs14:249-256.
Chen, X. et al., “Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents,” AbstractAmerican Assoc. of Pharmaceutical Scientists, vol. 9, No. 10, 1993.
Chu M. et al., “Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the FungusPenicillium griseofulvum”, Bioorganic and Medicinal Chemistry Letters9:1949-1952, 1999.
Chu M. et al., “Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor fromStreptomycessp.”,Tetrahedron Letters37:7229-7232, 1996.
Coe et al., “Preparation of Nucleotide Mimics with Potent Inhibitory Acti
Ishaq Khalid S.
Kucera Louis S.
Morris-Natschke Susan L.
Coleman Brenda
Morgan & Lewis & Bockius, LLP
University of North Carolina at Chapel Hill
Wake Forest University
Wilson James O.
LandOfFree
Lipid analogs for inhibiting the activity of hepatitis B... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid analogs for inhibiting the activity of hepatitis B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid analogs for inhibiting the activity of hepatitis B... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3825170